{
    "root": "1d80843a-79c4-4f80-851e-fe01885b9f7e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram Hydrobromide",
    "value": "20250303",
    "ingredients": [
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36"
        }
    ],
    "indications": "citalopram tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
    "contraindications": "• administer daily without food ( 2 ) . • initial 20 mg daily ; one week may increase maximum 40 mg daily ( 2.1 ) . • patients greater 60 years age , patients hepatic impairment , cyp2c19 poor metabolizers : maximum recommended 20 mg daily ( 2.2 ) . • discontinuing citalopram tablets , reduce gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions": "citalopram tablets , usp contain citalopram hydrobromide usp , equivalent 10 , 20 40 mg citalopram base . tan coloured , oval shaped , biconvex film coated tablets ‘ 2│0 ’ debossed ( ‘ 2 ’ left side ‘ 0 ’ right side break line ) one side ‘ 1010 ’ side . citalopram tablets , usp 40 mg bottle 30 ndc 68788-8962-3 bottle 60 ndc 68788-8962-6 bottle 90 ndc 68788-8962-9 bottle 100 ndc 68788-8962-1 bottle 120 ndc 68788-8962-8 tan coloured , oval shaped , biconvex film coated tablets ‘ 4│0 ’ debossed ( ‘ 4 ’ left side ‘ 0 ’ right side break line ) one side ‘ 1011 ’ side . storage handling store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "citalopram tablets contraindicated patients : • taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . • taking pimozide risk qt prolongation [ ( 7 ) ] . • known hypersensitivity citalopram inactive ingredients citalopram tablets . included angioedema anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14)] .",
    "contraindications_original": "• Administer once daily with or without food ( 2 ) . • Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ) . • Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ) . • When discontinuing citalopram tablets, reduce dosage gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions_original": "Citalopram Tablets, USP contain citalopram hydrobromide USP, equivalent to 10, 20 or 40 mg citalopram base.\n                  Tan coloured, oval shaped, biconvex film coated tablets with ‘2│0’ debossed (‘2’ on left side and ‘0’ on right side of the break line) on one side and ‘1010’ on the other side.\n                  Citalopram Tablets, USP 40 mg\n                  \n                     \n                         Bottle of 30 \tNDC 68788-8962-3\n                     \n                         Bottle of 60 \tNDC 68788-8962-6\n                     \n                         Bottle of 90 \tNDC 68788-8962-9\n                     \n                         Bottle of 100 \tNDC 68788-8962-1\n                     \n                         Bottle of 120 \tNDC 68788-8962-8\n                  \n                  Tan coloured, oval shaped, biconvex film coated tablets with ‘4│0’ debossed (‘4’ on left side and ‘0’ on right side of the break line) on one side and ‘1011’ on the other side.\n                  \n                     Storage and Handling\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Citalopram tablets are contraindicated in patients: • taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.3), Drug Interactions (7)] . • taking pimozide because of risk of QT prolongation [see Drug Interactions (7)] . • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis [see Adverse Reactions (6.2)] ."
}